Could Recro Pharma, Inc. (REPH) See a Reversal After This Very Strong Session?

March 14, 2018 - By Kurt Siggers

Investors sentiment decreased to 1.65 in 2017 Q3. Its down 0.56, from 2.21 in 2017Q2. It dropped, as 7 investors sold Recro Pharma, Inc. shares while 10 reduced holdings. 5 funds opened positions while 23 raised stakes. 9.63 million shares or 4.72% less from 10.10 million shares in 2017Q2 were reported.
State Of Wisconsin Invest Board reported 11,000 shares stake. Cadence Cap Ltd has invested 0.09% in Recro Pharma, Inc. (NASDAQ:REPH). Comml Bank Of America De reported 0% stake. Carl Domino invested in 0.31% or 28,000 shares. 42,878 are owned by Morgan Stanley. Deutsche Bank Ag reported 12,601 shares stake. Vanguard Gp holds 666,252 shares or 0% of its portfolio. New York-based New York State Common Retirement Fund has invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Jacobs Levy Equity Mgmt has 0.01% invested in Recro Pharma, Inc. (NASDAQ:REPH). Bnp Paribas Arbitrage Sa reported 0% in Recro Pharma, Inc. (NASDAQ:REPH). California State Teachers Retirement System holds 22,400 shares. Deerfield Mngmt holds 1.90M shares or 0.77% of its portfolio. Moreover, Barclays Public Limited Com has 0% invested in Recro Pharma, Inc. (NASDAQ:REPH). Janney Montgomery Scott Ltd Limited Liability Company, Pennsylvania-based fund reported 16,485 shares. Moreover, Dimensional Fund Advsrs Limited Partnership has 0% invested in Recro Pharma, Inc. (NASDAQ:REPH) for 129,560 shares.

Since December 12, 2017, it had 0 insider buys, and 5 sales for $1.43 million activity. On Thursday, January 4 SCP Vitalife Partners II LP sold $41,822 worth of Recro Pharma, Inc. (NASDAQ:REPH) or 4,732 shares. 93,237 shares valued at $919,128 were sold by Broadfin Healthcare Master Fund Ltd on Tuesday, December 12.

The stock of Recro Pharma, Inc. (NASDAQ:REPH) is a huge mover today! The stock increased 8.19% or $0.85 during the last trading session, reaching $11.23. About 581,041 shares traded or 221.32% up from the average. Recro Pharma, Inc. (NASDAQ:REPH) has risen 26.61% since March 14, 2017 and is uptrending. It has outperformed by 9.91% the S&P500.
The move comes after 6 months positive chart setup for the $215.13 million company. It was reported on Mar, 14 by We have $12.02 PT which if reached, will make NASDAQ:REPH worth $15.06 million more.

Analysts await Recro Pharma, Inc. (NASDAQ:REPH) to report earnings on May, 10. They expect $-0.68 earnings per share, down 61.90 % or $0.26 from last year’s $-0.42 per share. After $-0.63 actual earnings per share reported by Recro Pharma, Inc. for the previous quarter, Wall Street now forecasts 7.94 % negative EPS growth.

Recro Pharma, Inc. (NASDAQ:REPH) Ratings Coverage

Among 9 analysts covering Recro Pharma (NASDAQ:REPH), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Recro Pharma had 16 analyst reports since August 25, 2015 according to SRatingsIntel. Piper Jaffray maintained Recro Pharma, Inc. (NASDAQ:REPH) rating on Tuesday, July 25. Piper Jaffray has “Buy” rating and $1100 target. As per Monday, August 29, the company rating was initiated by Janney Capital. On Friday, September 16 the stock rating was initiated by TH Capital with “Buy”. On Tuesday, August 25 the stock rating was upgraded by Zacks to “Hold”. The firm earned “Buy” rating on Monday, October 3 by Brean Capital. Oppenheimer initiated Recro Pharma, Inc. (NASDAQ:REPH) on Tuesday, February 13 with “Buy” rating. The firm has “Overweight” rating by Piper Jaffray given on Monday, December 19. The firm earned “Buy” rating on Monday, November 14 by Aegis Capital. As per Friday, September 16, the company rating was initiated by Roth Capital. The company was maintained on Thursday, July 20 by Roth Capital.

More important recent Recro Pharma, Inc. (NASDAQ:REPH) news were published by: which released: “Recro Pharma Announces Commercial Team Additions” on March 02, 2018, also published article titled: “Recro Pharma to Present at Upcoming Investor Conferences”, published: “Recro Pharma Reports Year End 2017 Financial Results” on February 27, 2018. More interesting news about Recro Pharma, Inc. (NASDAQ:REPH) was released by: and their article: “Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam …” with publication date: February 20, 2018.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company has market cap of $215.13 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. It currently has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: